SCHEMBL5535131

SCHEMBL5535131

[CH2]c1cccc(Oc2cc(C(F)(F)F)cc(C(F)(F)F)c2)c1

nearest known ligand 0.51

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
KIF11 P52732 1/20 0.43
L3MBTL1 Q9Y468 3/20 0.40
NPSR1 Q6W5P4 2/20 0.40
CYP1A2 P05177 1/20 0.40
CYP2C9 P11712 1/20 0.40
CYP2C19 P33261 1/20 0.40
LTA4H P09960 1/20 0.40
TLR8 Q9NR97 6/20 0.39
TLR7 Q9NYK1 5/20 0.39
TEAD1 P28347 1/20 0.39
ALDH1A1 P00352 1/20 0.38
POLB P06746 1/20 0.38
MAPT P10636 2/20 0.38
ABCG2 Q9UNQ0 1/20 0.37
MAPK1 P28482 1/20 0.36
ADORA2A P29274 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6746131 0.91 KIF11 (0.50) KIF11L3MBTL1NPSR1CYP1A2CYP2C9
SCHEMBL5541954 0.86 KIF11 (0.46) KIF11L3MBTL1NPSR1LTA4HALDH1A1
SCHEMBL29230466 0.82 LTA4H (0.43) L3MBTL1NPSR1CYP1A2CYP2C9CYP2C19
SCHEMBL29723532 0.79 LTA4H (0.52) L3MBTL1NPSR1CYP1A2CYP2C9CYP2C19
SCHEMBL5542591 0.79 LTA4H (0.52) KIF11L3MBTL1NPSR1CYP1A2CYP2C9
SCHEMBL8307405 0.79 AR (0.54) L3MBTL1NPSR1CYP1A2CYP2C9CYP2C19
SCHEMBL9798371 0.78 LTA4H (0.54) KIF11L3MBTL1NPSR1CYP1A2CYP2C9
SCHEMBL4496102 0.77 RAB9A (0.41) TLR8TLR7ALDH1A1POLBMAPT
SCHEMBL28393851 0.76 TLR8 (0.50) L3MBTL1LTA4HTLR8TLR7
SCHEMBL5539559 0.76 ALDH1A1 (0.39) KIF11L3MBTL1NPSR1CYP2C9LTA4H

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2570418-A2 2,3-dihydro-6-nitroimidazo[2,1-b]oxazoles compound OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2013-03-20 EP disclosed
EP-1555267-B1 2,3-DIHYDRO-6-NITROIMIDAZO[2,1-b]OXAZOLES OTSUKA PHARMA CO LTD (JP) 2013-01-16 EP disclosed
US-7262212-B2 2,3-dihydro-6-nitroimidazo[2,1-b]oxazoles OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2007-08-28 US disclosed
US-20060094767-A1 2,3-Dihydro-6-nitroimidazo[2,1-b]oxazoles OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2006-05-04 US disclosed
CN-1705670-A 2, 3-dihydro-6-nitroimidazo [2, 1-b ] oxazole compounds OTSUKA PHARMA CO LTD (JP) 2005-12-07 CN disclosed
EP-1555267-A1 2,3-DIHYDRO-6-NITROIMIDAZO 2,1-b OXAZOLES OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2005-07-20 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060094767-A1 2,3-Dihydro-6-nitroimidazo[2,1-b]oxazoles NR2C2, NR4A3, NR4A2 KIF11 3946/4885L3MBTL1 1931/4885NPSR1 747/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.